louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06450522: Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF)
Official title: Post-Discharge Pharmacist-led Rapid Medication Optimization for Heart Failure (Post-Discharge PHARM-HF): a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Heart Failure with Reduced Ejection Fraction HFrEF
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2024-06-10
Enrollment: 12
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will recruit 100 patients from a post-discharge medicine clinic to test if the addition of a pharmacist to manage heart failure medications can increase appropriate use of these medications. Participants will be randomly assigned to usual care alone or with the addition of a pharmacist to help manage medications. They will be followed for 3 months by telephone/electronically-administered questionnaires, and 12 months using administrative health records. Outcome data will include information from patients on quality of life, treatment burden, medication adherence, as well as information from their medical record on heart failure events.


Eligibility criteria: Inclusion Criteria:

1. Age ≥19 years;
2. Attending their initial visit to the PDMC;
3. Diagnosis of HF.

Exclusion Criteria:

* None.

Primary outcomes:
measure: Optimization Potential Score
timeFrame: 3 months
Secondary outcomes:
measure: Composite hierarchical outcome
timeFrame: 3 months
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: St. Paul's Hospital
state: British Columbia
Study officials:
References:
Clinical trial NCT02741622: Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.
Official title: Effects of Aerobic Exercise Intensity on Affective States and Brain Derived Neurotropic Factor in Patients With Depression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depressive Disorder
Depressive Disorder, Major
Keywords: Exercise therapy
Lead sponsor: St. Olavs Hospital
Sponsor class: OTHER
Collaborators: name: Norwegian University of Science and Technology
First posted: 2016-04-18
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Acute aerobic exercise improves affective stats in patients with mental illnesses. Brain derived neurotropic factor (BDNF) may be a biological mechanism that contributes to the affective benefits. The magnitude of the increase of serum BDNF might be exercise intensity dependent, but no study has compared low high-aerobic-intensity training at 90-95 % of the maximal heart rate (HRmax) with long-slow-distance training at 70 % of the HRmax in patients with depression.

The aim of this study is to compare changes in serum BDNF levels after high-aerobic-intensity training and long-slow-distance training in a intra-individual design in patients suffering from depression. The results will give indications of a possible difference in BDNF response between aerobic intensities and may be uses as pilot data for calculating sample size.


Eligibility criteria: Inclusion Criteria:

* Moderate or severe depression (ICD10: F32-F33)

Exclusion Criteria:

* Bipolar disorder.

Primary outcomes:
measure: Change in serum brain derived neurotropic factor (BDNF)
timeFrame: 15 minutes before exercise to 5> minutes after exercise.
Secondary outcomes:
measure: Change in affective symptoms
timeFrame: 15 minutes before exercise to 15> minutes after exercise.
measure: Change in state of anxiety.
timeFrame: 15 minutes before exercise and 15> minutes after exercise.
measure: Change in subjective exercise experience
timeFrame: 15 minutes before exercise to 15> minutes after exercise.
measure: Maximal oxygen uptake
timeFrame: Baseline
measure: Maximal Heart rate
timeFrame: Baseline
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St.Olavs university Hospital, Departement of Østmarka
Study officials:
affiliation: St.Olavs University Hospital, Østmarka
name: Pål Sandvik, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05687422: Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy
Official title: A Randomized Controlled Study of Two Patterns of Micropulse Laser in the Treatment of Chronic Central Serous Chorioretinopathy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Central Serous Chorioretinopathy
Lead sponsor: Beijing Hospital
Sponsor class: OTHER_GOV
First posted: 2023-01-18
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Central serous chorioretinopathy (CSC) is a common eye disease mainly involving the macular area, causing central visual acuity loss. Recently, subthreshold micropulse laser used in treating chronic CSC is proved to be safe and effective. However, some studies indicate that it's less effective than half dose photodynamic therapy (PDT). Certain physicians, including us, think that this may be related to micropulse laser parameters. Thus we need to explore better laser patterns to replace PDT in treating chronic CSC. The aim of this study is to compare the treatment effect of two different patterns of laser parameters (small and regular spot diameter) in treating chronic CSC. In this randomized, double blinded, controlled trial, by comparing the subretinal fluid regression ratio, central retinal thickness, macular microvisual field, macular vascular density, chroidal volume changes and visual acuity of two groups 6 months after micropulse laser treatment, we aim to evaluate the safety and efficacy of refined micropulse laser in treating chronic CSC.


Eligibility criteria: Inclusion Criteria:

* Patients age range 18-50 years
* Patients diagnosed with chronic Central serous chorioretinopathy
* Patients have signed informed consent

Exclusion Criteria:

* A history of other fundus diseases or refractive media opacity
* Patients have underwent other treatment methods for chronic Central serous chorioretinopathy
* Diopter\>-6D
* A history of system diseases such as hypertension or diabetes
* A history of using local or systemic corticosteroids

Primary outcomes:
measure: Subretinal fluid regression ratio
timeFrame: 6 months
measure: Central retinal thickness changes
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04397822: COVID-19 : Study of INFLAmmasome and PLAtelets Functions
Official title: Study of INFLAmmasome NLRP3 and PLAtelets Functions During Severe COVID-19 Infection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Keywords: COVID-19
NLRP3 inflammasome
Platelets functions
Coagulopathy
Acute respiratory distress syndrome
Lead sponsor: University Hospital, Toulouse
Sponsor class: OTHER
First posted: 2020-05-21
Enrollment: 61
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from COVID-19, hospitalized in intensive care unit and in standard care unit.

Brief summary: COVID-19 pandemic is a severe viral sepsis characterized by the occurrence of Acute respiratory distress syndrome (ARDS) whose pathophysiology is little described

Detailed description: The new Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic started on December 2019 in China and spreaded in worldwide. The Coronavirus disease 2019 (COVID-19) is responsible of case of severe pneumonia whose the major risk is the development to ARDS. Concerning the pathophysiology, there appear to be hemostasis abnormalities including thrombocytopenia and coagulopathy. In recent studies, this thrombocytopenia is described as a risk factor to develop severe COVID-19 infection. Sepsis is associated with a major systemic inflammatory response with an increased production of pro-inflammatory cytokines. Since their discovery, inflammasomes have an important role during inflammatory response following an aggression. There are intracytoplasmic multiprotein complex activated by cellular stress or infections and is responsible for the release of pro-inflammatory cytokines, including IL-1β. Most studies have analysed inflammasomes in nucleated cells, nevertheless, little is known about inflammasomes in platelets.

Thus, the present work aims to study the activation of the platelet NLRP3 inflammasome and the platelet functions and coagulation during a SARS-CoV-2 viral pneumonia according to different levels of severity

Eligibility criteria: Inclusion Criteria:

* Patients suffering from COVID-19, hospitalized in intensive care unit and in standard care unit.

Exclusion Criteria:

* Patients suffering from malignant blood disease, cryopyrinopathy, sickle cell disease, rheumatoid arthritis and Crohn's disease

Primary outcomes:
measure: Activation of platelet NLRP3 inflammasome
timeFrame: Day 0 During resuscitation (Covid-19 Resuscitation) or hospitalization (Covid-19 No Resuscitation)
measure: Activation of platelet NLRP3 inflammasome
timeFrame: During Day 0 During resuscitation (Covid-19 Resuscitation) or hospitalization (Covid-19 No Resuscitation)
Secondary outcomes:
Other outcomes:
Locations:
city: Toulouse
country: France
facility: CHU Toulouse
Study officials:
affiliation: University Hospital, Toulouse
name: Fanny BOUNES
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05058222: Effect of Deep Breathing Exercises on Post Operative Sleep Duration
Official title: Effect of Deep Breathing Exercises on Post Operative Sleep Duration and Quality in Patients Undergoing CABG (Coronary Artery Bypass Graft).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Bypass Graft
Keywords: Breathing exercises
Coronary artery bypass
Sleep
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2021-09-27
Enrollment: 28
Sex: ALL
Minimum age (years): 30
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will provide the evidence that during the postoperative period deep breathing exercise combined with physical training can positively influence the sleep duration and quality. This study will provide the evidence that during the postoperative period deep breathing exercise combined with physical training can positively influence the sleep duration and quality.

Detailed description: Subjects will be randomly placed into Control group and Interventional group. The control program will consist of Deep Breathing Exercises (from Morning to night every three hours; each session consisting of 10 deep breaths with a few seconds pause between each set, for 3 days) in addition with progressive Exercises. Two daily sessions with an average duration of 25 min will be performed. In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform additional Deep breathing Exercises (from Morning to night every three hours; each session consisting of 30 deep breaths with a few seconds pause between each set, for 3 days). Deep breathing exercises will start 48 hours after extubation and full education along with the routine care (i.e.: from the fourth to sixth postoperative day).

Eligibility criteria: Inclusion Criteria:

* Ability to read and write
* Stabilization of vital signs \[blood pressure, pulse, respiration)
* Patient undergoing OFF Pump Coronary Artery Bypass Graft (CABG) Procedure

Exclusion Criteria:

* History of severe mental diseases resulting in hospitalization and drug treatment within the previous 6 months
* Use any kind of other complementary methods such as massage therapy, aromatherapy, etc. to treat sleep disorders for the previous two weeks
* History of sleep or respiration disorders and used CNS medications in the night.

Primary outcomes:
measure: St Mary's Hospital Sleep Questionnaire (SMHSQ)
timeFrame: Baseline
measure: St Mary's Hospital Sleep Questionnaire (SMHSQ)
timeFrame: 3 week
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Armed forces Institute of Cardiology
state: Punjab
Study officials:
affiliation: Riphah college of rehabilitation and allied health sciences - Rawalpindi
name: Anam Aftab, Phd*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00690222: Intracameral Mydriasis Versus Topical Mydriasis in Cataract Surgery
Official title: A Comparison of Intracameral Phenylephrine 2% and Tropicamide 0.2% With Topical Phenylephrine 2.5% and Tropicamide 1% for Pupillary Dilation During Cataract Surgery on Patients With and Without Pseudoexfoliation Syndrome.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Cataract
Phacoemulsification
Mydriasis
Pseudoexfoliation Syndrome
Keywords: cataract surgery
phacoemulsification
pupil
dilation
mydriasis
intracameral
topical
pseudoexfoliation syndrome
Lead sponsor: Nova Scotia Health Authority
Sponsor class: OTHER
First posted: 2008-06-04
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose is to determine if an intracameral solution of 0.2% tropicamide and 2% phenylephrine can dilate the pupil for cataract surgery as well as pre-operative topical 1% tropicamide and 5% phenylephrine. We will be looking at two separate groups of patients, those with and those without pseudoexfoliation syndrome.

We will be looking at how each method affects the size of the pupil at the beginning and at the end of cataract surgery. In addittion, we will look at what effect the two different methods have on blood pressure and heart rate in the pre-operative, peri-operative and post-operative periods.


Eligibility criteria: Inclusion Criteria:

* Ability to give consent
* Greater than 18 years of age
* Planned clear cornea cataract extraction and placement of foldable posterior chamber intraocular lens
* No secondary procedure planned (i.e. trabeculectomy, keratectomy, corneal transplant, vitreo-retinal procedure etc.)
* Systemic condition capable of undergoing topical anesthesia
* No previous intraocular surgery
* Pseudoexfoliation syndrome (PXF) for group 1
* No Pseudoexfoliation syndrome for group 2

Exclusion Criteria:

* Not fulfilling inclusion criteria
* Any iris pathology including but not limited to posterior synechia, iridocorneal endothelial syndrome, corectopia, traumatic mydriasis, Horner's syndrome, Adie's pupil, cyclodialysis, iridodialysis
* Previous or concurrent use of Flomax® or similar alpha-antagonist medication
* Corneal pathology affecting pupil magnification or measurement (keratoconus, peripheral thinning, sclerocornea, scarring)
* Uncontrolled Hypertension (greater than 170/90 on pre-operative assessment on day of surgery as measured by automated DATEX monitor)

Primary outcomes:
measure: Pupil size
timeFrame: At beginning and completion of cataract surgery
Secondary outcomes:
measure: Blood pressure
timeFrame: Peri-operatively
measure: Heart rate
timeFrame: Peri-operatively
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Capital District Health Authority
state: Nova Scotia
Study officials:
References:
Clinical trial NCT02469922: Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer
Official title: Prospective Study Assessing Predictive Value of 18 F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose (FDG) Positron Emission Tomography During Radio-chemotherapy for Locally Advanced Epidermoid Carcinoma of Head and Neck
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malignant Neoplasm of Head and Neck
Locally Advanced Malignant Neoplasm
Lead sponsor: Center Eugene Marquis
Sponsor class: OTHER
First posted: 2015-06-12
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Open multicentric study assessing predictive value of 18-FDG PET (SUV max) at 20 Gy during radio-chemotherapy, on the loco-regional control after 2 years


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years and ≤ 75 years
* invasive epidermoid carcinoma of head and neck (excluding nasopharyngeal), confirmed by histology
* locally advanced disease (non-metastatic stages AJCC III-IV). AJCC = American Joint Committee on Cancer
* performance status ECOG ≤ 2. ECOG = Eastern Cooperative Oncology Group
* no history of irradiation of the head and neck
* start of radiotherapy within 8 weeks after the pretreatment PET Scan
* no surgery other than biopsy
* pregnancy test: negative for women of childbearing potential
* reliable contraception for a childbearing couple, men and woman must have a reliable contraception during treatment
* signed informed consent form
* patient with national health insurance

Exclusion Criteria:

* prior radiotherapy or chemotherapy
* history of other cancer except: cutaneous non-melanoma tumor and cervix in situ carcinoma
* unstable conditions (cardiovascular, renal, pulmonary) or systemic (lupus erythematosus, scleroderma)
* pregnant patient or patient with breastfeeding
* patient unable to give his consent
* patient under administrative supervision
* patient who participates to another clinical trial on experimental drug
* regular follow-up impossible for various reasons (familial, economical, social, ...)
* diabetes
* accelerated radiotherapy protocol

Primary outcomes:
measure: Locoregional relapse
timeFrame: 2 years
Secondary outcomes:
measure: Comparison of TEP scan values (Standardized Update Value max, Metabolic Tumor Volume)
timeFrame: pretreatment, 15 days, 29 days, 3 months post treatment
Other outcomes:
Locations:
city: Brest
country: France
facility: CHU Brest
city: Le Mans
country: France
facility: Centre jean Bernard - Rue Victor Hugo
city: Lorient
country: France
facility: Hôpital du Scorff
city: Rennes
country: France
facility: Centre Eugene Marquis
city: Saint Grégoire
country: France
facility: Centre d'Oncologie St Vincent - Boulevard de la Boutière
Study officials:
affiliation: Centre de Lutte Contre le Cancer Centre Eugène Marquis
name: Castelli Joël, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01869322: Acute Management of Humeral Shaft Fractures: Sling vs. Splint
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fracture of Shaft of Humerus
Keywords: Humerus
Fracture
Sling
Splint
Coaptation
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2013-06-05
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: When people break their arm and arrive at Oregon Health and Science University's Emergency Department (OHSU ED), they are treated with a short-term means of immobilizing their broken arm. The two most common ways of stabilizing the broken parts of the arm are 1) with a plaster-based coaptation splint, or 2) with a soft cloth sling and swathe. These hold the arm steady until the patient can schedule an appointment with the OHSU Orthopaedic Trauma clinic where they will receive definitive evaluation and stabilization/fixation. In much of the orthopaedic literature coaptation splints are the default immobilization method. The investigators hypothesize however, that sling and swathe immobilization may be equally effective for short term stabilization, while being faster to apply, and more comfortable for the patient. This randomized, unblinded prospective study will follow the satisfaction, quality of life and limited functional outcomes of all enrolled participants during the first week following their injury.


Eligibility criteria: Inclusion Criteria:

* age 18-80
* acute midshaft humeral fracture within 48 hours

Exclusion Criteria:

* ED presentation more than 48 hours after injury
* Head injury
* Open fracture
* Pathological fracture
* Known pregnancy
* Inmate or prisoner
* Non-English speaking
* Sexual Assault (SA) victim
* Patient and Legally Authorized Representative unable to provide consent

Primary outcomes:
measure: Patient Satisfaction
timeFrame: 5 days
Secondary outcomes:
measure: Patient Pain
timeFrame: 5 days
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Darin Friess, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03742622: Energy Intake, Exercise and Energy Replacement
Official title: Does Energy Replacement Modify Post-exercise Energy Intake in Adolescents With Obesity?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Obesity
Keywords: appetite control
obesity
Adolescents
exercise
Energy replacement
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: Tza Nou - Maison médicale pour enfants et adolescentes - 230, rue Vercingétorix - B.P. 77 - 63150 La Bourboule
name: SSR Nutrition-Obésité - 33-35 rue Maréchal Leclerc - 63000 Clermont-Ferrand
name: Université d'Auvergne
First posted: 2018-11-15
Enrollment: 14
Sex: ALL
Minimum age (years): 12
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to compare the effect of an exercise alone versus. An exercise followed by the ingestion of an energy replacement snack on the following energy intake, food reward and appetite feelings in adolescents with obesity.

Detailed description: The present study will compare the nutritional response to the realisation of an acute exercise with and without an energy replacement snack on the following energy intake in adolescents with obesity. 18 adolescents with obesity will be asked to randomly complete three experimental sessions: i) one control session (rest); ii) one session with an acute exercise realized during the morning; iii) one session with the same exercise followed by a snack covering the exercise-induced energy expenditure. Their ad libitum energy intake will be assessed at the following meal as well as at dinner time. Appetite feelings will be assessed at regular intervals and their food reward in response to the lunch will also be assessed.

Eligibility criteria: Inclusion Criteria:

* BMI percentile \> 97th percentile according to the french curves.
* ages 12-16 years old
* Signed consent form
* being registered in the national social security system
* no contraindication to physical activity

Exclusion Criteria:

* Previous surgical interventions that is considered as non-compatible with the study.
* Diabetes
* weight loss during the last 6 months
* cardiovascular disease or risks

Primary outcomes:
measure: Energy intake measured during an ad libitum buffet meal (in kcal).
timeFrame: at lunch (at day 1)
Secondary outcomes:
measure: Measurement of hunger feelings
timeFrame: at day 1
measure: Food reward
timeFrame: at day 1
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: Chu Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Yves BOIRIE
role: PRINCIPAL_INVESTIGATOR
References: